23 September 2021 03:00 PM
WEBINAR: Lecture series Cancer Research: "Myeloid Cells in Glioblastoma" - Prof Dolores Hambardzumyan
16 September 2021 11:00 AM
WEBINAR: Lecture series in Infection & Immunity - "The COVID-19 pandemic and the response by the scientific community in Luxembourg" - Prof Paul Wilmes
Luxembourg rewarded for its translational medicine excellence
In August 2021, the Luxembourg node of the European Research Infrastructure for Translational Medicine (EATRIS) network was granted the EATRIS Node Reward Framework award for its significant contribution to the efforts and impact of the European infrastructure in advancing translational medicine in 2020.
LIH scientist at the forefront of European nutritional health
On July 1st 2021, Dr Torsten Bohn from the Nutrition and Health Research Group (DoPH), became part of the European Food Safety Authority (EFSA) panel for Nutrition, Novel Foods and Allergens (NDA). This highly sought-after position makes Dr Bohn one of only 16 external EFSA experts able to advise on Diet and Health decisions for the whole of Europe.
Personalised medicine of obesity: An innovative tool to diagnose visceral fat
A fruitful collaboration between Research and Development teams* of the Luxembourg Institute of Health and the Centre Hospitalier de Luxembourg (CHL) enabled the development of the Visceral Fat Calculator, an online tool providing an accurate and easy evaluation of the visceral fat depots for adults.
[Press release] Advancing the treatment of Parkinson’s disease
The Luxembourg Institute of Health (LIH) and the Centre Hospitalier de Luxembourg (CHL) announce the launch of “SCOL” (Study of Continuous Oral Levodopa), a unique international clinical trial aiming to assess the safety, tolerability and efficacy of the new DopaFuse System for the continuous oral delivery of levodopa to better treat the symptoms of Parkinson’s Disease. The clinical trial, which is being conducted concomitantly in Italy, Spain and Luxembourg, has the potential to revolutionise the treatment of this common neurodegenerative disease by facilitating drug delivery and reducing side effects.
Enabling precision cardiometabolic disease prevention through artificial intelligence
Researchers from the LIH Department of Population Health (DoPH) and from the LIH Quantitative biology Unit (QBU) leveraged advanced artificial intelligence and machine-learning approaches to classify a sample of individuals representative of the Luxembourgish population into distinct risk groups, paving the way towards more targeted strategies for the prevention of cardiometabolic diseases at a population level. The findings were published on August 6th 2021 in the Nature Portfolio journal “Scientific Reports”.
Making large-scale health data analysis a reality
The Luxembourgish National Cancer Registry (RNC) at LIH joined the consortium of the European Health Data & Evidence Network (EHDEN). The LIH team, which involves the RNC, the IT eXpertise in Health Data (IT-X-HD) and the Deep Digital Phenotyping Research Unit of the LIH Department of Population Health (DoPH), as well as the IT company Information Technology for Translational Medicine (ITTM), secured a cross-disciplinary grant for a duration of 12 months to accelerate the standardisation of clinical data.